Skip to main content

Central Serous Retinopathy

Fluid buildup under the macula causing blurred or distorted central vision, often linked to stress and corticosteroids. Learn about causes, prognosis, and treatment.

6 min read

Central serous retinopathy (CSR), also called central serous chorioretinopathy (CSCR), occurs when fluid leaks under the macula from the layer beneath the retina (the retinal pigment epithelium, or RPE). This creates a small "blister" of fluid that lifts the retina, causing blurred or distorted central vision. Most acute episodes resolve on their own, but chronic or recurrent cases may need treatment.

Key Takeaways

  • Fluid accumulates under the macula, causing blurred and distorted central vision
  • Strongly associated with stress and corticosteroid use (oral, inhaled, nasal, topical)
  • Most common in men ages 30-50
  • Acute CSR usually resolves on its own within 3-4 months
  • Chronic CSR (lasting >4-6 months) may require treatment to prevent permanent damage
  • OCT clearly shows the subretinal fluid
  • Stopping corticosteroids (when possible) is the most important first step

Overview

Central serous retinopathy is a relatively common condition that tends to affect young to middle-aged adults, particularly men. While it can be alarming, acute CSR has an excellent prognosis — most episodes resolve spontaneously with full or near-full recovery of vision. However, chronic or frequently recurring CSR can lead to progressive retinal damage and permanent vision changes.

Symptoms

  • Blurred vision in one eye (usually)
  • Distorted vision (metamorphopsia) — straight lines appear bent
  • Central dark or dim spot
  • Objects appear smaller than normal (micropsia) in the affected eye
  • Colors may appear washed out or duller in the affected eye
  • Reduced contrast sensitivity
  • May be asymptomatic if the fluid is not directly under the fovea

Causes and Risk Factors

The Mechanism

The retinal pigment epithelium (RPE) normally acts as a barrier, keeping fluid from the choroid (blood vessel layer) away from the retina. In CSR, this barrier breaks down at one or more points, allowing fluid to seep under the retina.

Major Risk Factors

  • Stress and "type A" personality — the classic association
  • Corticosteroid use — the strongest modifiable risk factor
    • Oral prednisone
    • Inhaled steroids (for asthma)
    • Nasal steroid sprays
    • Steroid creams (even on distant skin)
    • Steroid joint injections
  • Male sex (6:1 male-to-female ratio)
  • Age 30-50
  • Pregnancy (usually resolves after delivery)
  • Obstructive sleep apnea
  • Helicobacter pylori infection (association reported)
  • Organ transplant (due to chronic steroid/immunosuppressive use)

Diagnosis

  • Optical coherence tomography (OCT) — clearly shows the dome of subretinal fluid under the macula; essential for diagnosis and monitoring
  • Fluorescein angiography — shows the point of leakage (classic "smokestack" or "inkblot" pattern); helps guide laser treatment if needed
  • Indocyanine green (ICG) angiography — evaluates the choroidal blood flow; helpful in chronic cases
  • Fundus autofluorescence — detects RPE changes, especially in chronic CSR
  • Visual acuity testing — typically 20/20 to 20/40 in acute cases

Treatment

Acute CSR

Observation (first-line):

  • Most acute episodes resolve spontaneously in 3-4 months
  • Stop corticosteroids if possible (the single most important intervention)
  • Reduce stress — exercise, sleep, relaxation techniques
  • Treat sleep apnea if present
  • Monitor with monthly OCT

Chronic or Recurrent CSR

If fluid persists beyond 4-6 months or vision deteriorates:

Photodynamic therapy (PDT):

  • The most effective treatment for chronic CSR
  • Low-fluence (half-dose) PDT is preferred to minimize side effects
  • Targets the abnormal choroidal vessels causing the leak
  • High success rate (>80% fluid resolution)

Focal laser photocoagulation:

  • Applied directly to the leakage point
  • Only used when the leak is well away from the foveal center
  • Quick and effective but can create a small blind spot

Anti-VEGF injections:

  • Less effective than PDT for typical CSR
  • May be used in combination with PDT
  • More helpful when there is associated choroidal neovascularization

Mineralocorticoid antagonists (oral):

  • Eplerenone or spironolactone
  • Some evidence of benefit in chronic CSR
  • Used as an adjunct or when PDT is unavailable

Prognosis

Acute CSR

  • Excellent — most resolve within 3-4 months
  • Vision typically returns to 20/20 or near-normal
  • Subtle changes in color perception or contrast may persist
  • Recurrence rate: 30-50% over subsequent years

Chronic CSR

  • More guarded — prolonged fluid causes progressive RPE and photoreceptor damage
  • Treatment can resolve fluid but some visual changes may be permanent
  • Long-term monitoring is important

When to See a Doctor

See an eye doctor if you notice:

  • New blurring of central vision, especially in one eye
  • Distortion of straight lines
  • A dim or dark spot in your central vision
  • Objects looking smaller or colors looking different in one eye compared to the other

Frequently Asked Questions

Will CSR go away on its own?

Most acute episodes do resolve spontaneously within 3-4 months. However, chronic cases lasting longer than 4-6 months usually require treatment to prevent permanent retinal damage.

Can stress really cause an eye problem?

Yes. CSR is one of the clearest examples of stress affecting the eyes. The mechanism likely involves stress hormones (cortisol) affecting the choroidal blood vessels and RPE barrier. Stress reduction is a genuine part of treatment.

How long should I wait before getting treatment?

For a first episode with good visual acuity, most ophthalmologists recommend observing for 3-4 months. If fluid is still present, the vision is significantly affected, or you've had multiple recurrences, earlier treatment may be appropriate.

Can I prevent recurrences?

Avoiding corticosteroids, managing stress, treating sleep apnea, and maintaining overall health can reduce recurrence risk. However, some patients have recurrences despite these measures.

CSR and macular degeneration are different conditions. However, chronic CSR can sometimes be confused with certain forms of macular degeneration, and long-standing CSR can cause retinal changes resembling those of macular degeneration. Your ophthalmologist can distinguish between them.

References

Was this article helpful?